Background: The LBCRS was developed out of autopsy verified cases and has been originally validated with 25 healthy controls, 24 AD (Alzheimer disease) – and 20 DLB-individuals. Further on it was applied on patients with memory disorder background and compared with gold standard measures in two cross-sectional studies. It demonstrated successful discrimination between DLB and AD as well as DLB and frontotemporal degeneration and between mild cognitive impairment (MCI) due to DLB versus MCI-AD.

Methods: The Luxembourg Parkinson’s Study includes a longitudinal follow-up over 4 years where quantitative and biological data are collected from 800 Parkinson subjects and controls. LBCRS’s 10 questions will be integrated in the eCRF which already contains 8 of 10 questions from LBCRS (question 1-5, 8-10) in its standard assessment. Scores can be directly derived and automatically filled in from MDS-UPDRS III (questions 1, 2, 3, 4), MDS-UPDRS I (questions 5 and 8) and anamnestic data (questions 9 and 10). Only questions 6 and 7 need to be added into the eCRF.

Results: Conclusive results regarding to LBCRS’s longitudinal properties can be obtained by following the evolution of the LBCRS and comparing with an eventual outcome of DLB at follow-up. Pathological validation is aimed in the future by implementing a brain bank within an EU funded project.

Conclusions: LBCRS longitudinal properties are testable in an uncomplicated, time-sparing way by integrating it in the existing eCRF defined for the the Luxembourg Parkinson’s Study.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-luxembourg-parkinsons-study-integrating-the-lewy-body-composite-risk-score-into-a-longitudinal-study/